Education
The Week in Diabetes & Endocrinology — Episode 003 | April 17, 2026
From Hormone Insight (hormoneinsight.com)
Six stories this week that endocrinologists, diabetologists, and internists need to know.
TIMESTAMPS:
0:00 — Introduction & This Week's Stories
1:15 — Automated Insulin Delivery in Type 2 Diabetes: A Landmark Trial Worth Unpacking
5:30 — Enlicitide: The First Oral PCSK9 Inhibitor (CORALreef Lipids)
9:30 — SCORED and Sotagliflozin: What the Trial Actually Tells Us
12:30 — Semaglutide in Type 1 Diabetes + Obesity (NEJM Evidence)
15:00 — Boehringer Ingelheim's Strategic Bet on Obesity + Liver Health
16:30 — Chronotype-Aligned Exercise: Timing May Matter as Much as Training
18:00 — Closing Thoughts
REFERENCES & SHOW NOTES:
▸ AID in T2D (NEJM, 2IQP trial): https://doi.org/10.1056/NEJMoa2415948
▸ Enlicitide CORALreef Lipids (Med): https://doi.org/10.1016/j.medj.2026.101097
▸ CORALreef Lipids primary (NEJM): https://doi.org/10.1056/NEJMoa2511774
▸ Semaglutide in T1D + obesity (NEJM Evidence): https://doi.org/10.1056/EVIDoa2500173
▸ Chronotype-aligned exercise RCT (Open Heart): https://doi.org/10.1136/openhrt-2025-003573
ABOUT THIS PODCAST:
A weekly evidence-based review of the top stories in diabetes, obesity, thyroid, and endocrinology — modeled on Medscape's "This Week in Cardiology." New episodes every Thursday. For healthcare professionals.
▸ Website: https://hormoneinsight.com
▸ Full show notes: https://hormoneinsight.com/podcast
DOWNLOAD THE APP:
▸ iOS: https://apps.apple.com/dz/app/hormone-insight/id6749515856
▸ Android: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl
️ This content is intended for healthcare professionals. It does not constitute medical advice for patients.
#Endocrinology #DiabetesResearch #AutomatedInsulinDelivery #PCSK9 #Enlicitide #Sotagliflozin #SCORED #Semaglutide #Type1Diabetes #Survodutide #Obesity #MASH #Chronotype #Exercise #MedicalPodcast #HormoneInsight #CME #MedTwitter #DoctorsOfYouTube #EvidenceBasedMedicine #Tirzepatide